Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Sionna Therapeutics, Inc. Common Stock (SION)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SION (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $
1 Year Target Price $
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.82% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 7.25 - 25.19 | Updated Date 06/7/2025 |
52 Weeks Range 7.25 - 25.19 | Updated Date 06/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 5 | Target Price - | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sionna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing highly effective and best-in-class therapies for cystic fibrosis (CF). Founded in 2019, the company is focused on restoring CFTR function to address the underlying cause of the disease for all people with CF.
Core Business Areas
- Drug Development: Focuses on discovering, developing, and commercializing novel therapeutics for CF. Their lead candidate, SION-638, is a novel small molecule designed to inhibit the interaction between NHERF1 and CFTR, aiming to improve CFTR function.
Leadership and Structure
Sionna Therapeutics is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- SION-638: SION-638 is an investigational NHERF1 inhibitor aimed at treating CF. It's currently in clinical trials. Market share is currently 0% due to it being an investigational drug. Competitors include Vertex Pharmaceuticals with their CFTR modulators.
Market Dynamics
Industry Overview
The CF therapeutics market is dominated by CFTR modulators. There is unmet need for therapies that address all patients with CF, including those not eligible for or who do not respond adequately to existing treatments.
Positioning
Sionna Therapeutics aims to address the unmet need in CF treatment by targeting NHERF1, a novel mechanism distinct from existing CFTR modulators, offering a potential treatment option for a broader range of CF patients.
Total Addressable Market (TAM)
The global cystic fibrosis market is expected to reach over $13 billion by 2030. Sionna aims to capture a significant portion by providing an alternative treatment. The TAM is addressable to the degree SION-638 reaches more than CFTR modulators.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (NHERF1 inhibition)
- Potential to address unmet needs in CF treatment
- Experienced management team
- Strong intellectual property position
Weaknesses
- Early-stage clinical development (high risk)
- Dependence on a single lead candidate
- Requires substantial funding for clinical trials and commercialization
- Limited operating history as a public company
Opportunities
- Expansion of clinical trials to new patient populations
- Partnerships with pharmaceutical companies
- Potential for breakthrough therapy designation
- Expansion to other indications besides cystic fibrosis
Threats
- Clinical trial failures
- Competition from established CFTR modulators
- Regulatory hurdles
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- VRTX
Competitive Landscape
Vertex Pharmaceuticals dominates the CF market with its CFTR modulators. Sionna Therapeutics seeks to challenge this dominance by offering a different therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: As a newly formed company, there is no historical revenue growth at this moment.
Future Projections: Future projections depend on the success of SION-638's clinical trials and its eventual commercialization.
Recent Initiatives: Focusing on advancement of SION-638, a novel small molecule.
Summary
Sionna Therapeutics is a clinical-stage biopharmaceutical company with a focus on treating cystic fibrosis by pursuing a novel target. Being early-stage, their future success is closely tied to clinical trials of SION-638. With no other product offerings at this time, they could face threats if their product is not successful and they are dependent on securing funds. Success here will mean positive investor relations and potentially a new offering to help CF patients.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market data and analyst estimates are subject to change. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sionna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2025-02-07 | President, CEO & Director Mr. Michael Cloonan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 48 | Website https://www.sionnatx.com |
Full time employees 48 | Website https://www.sionnatx.com | ||
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.